Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy.

Abstract:

:We present 60 patients with refractory (n=8) or relapsed (n=52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n=41) or without (n=19) prior reinduction chemotherapy. In our center, omission of reinduction is recommended if a suitable donor is promptly available, tumor burden is moderate and disease features suggest a highly aggressive course. Overall survival (OS) of the whole cohort at 1, 2 and 5 years was 42, 33 and 28%, respectively. Leukemia-free survival at 1, 2 and 5 years was 37, 33 and 24%. Deaths were due to relapse (n=25), acute or chronic GVHD (n=7), infections (n=8) or toxicity (n=4). Interestingly, patients who did not receive reinduction before HSCT had better outcomes than patients who received reinduction with OS at 1, 2 and 5 years being 58 vs 34%, 47 vs 25% and 47 vs 18%, respectively (P=0.039). Importantly, even achievement of a second CR after reinduction was not associated with improved survival compared to patients directly proceeding to HSCT. We conclude that patients who undergo HSCT for refractory or relapsed ALL can achieve long-term survival. In selected patients, reinduction chemotherapy can be omitted if immediate HSCT is feasible.

journal_name

Bone Marrow Transplant

authors

Terwey TH,Massenkeil G,Tamm I,Hemmati PG,Neuburger S,Martus P,Dörken B,Hoelzer D,Arnold R

doi

10.1038/bmt.2008.258

subject

Has Abstract

pub_date

2008-12-01 00:00:00

pages

791-8

issue

12

eissn

0268-3369

issn

1476-5365

pii

bmt2008258

journal_volume

42

pub_type

杂志文章
  • Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.

    abstract::We examined whether pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is capable of improving thrombocytopenia and promoting thrombopoietic reconstitution following lethal irradiation and bone marrow transplantation (BMT) in mice. Immediately after receiving 10 Gy whole body irradia...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Kabaya K,Shibuya K,Torii Y,Nitta Y,Ida M,Akahori H,Kato T,Kusaka M,Miyazaki H

    更新日期:1996-12-01 00:00:00

  • Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry.

    abstract::A questionnaire comprised of a series of clinical vignettes illustrating potential difficulties in diagnosis, grading and treatment of chronic graft-versus-host disease (GVHD) was completed by 65 bone marrow transplant physicians from 51 transplant centers worldwide. The concordance index (CI) for responses to each qu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Atkinson K,Horowitz MM,Gale RP,Lee MB,Rimm AA,Bortin MM

    更新日期:1989-05-01 00:00:00

  • Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study.

    abstract::The frequency of CTL precursors (CTLp) directed towards recipient-derived pre-transplant leukaemic blasts (LB) was measured in the peripheral blood of nine children with acute leukaemia and given BMT from either an HLA-identical sibling or a matched unrelated donor (MUD). Patients were evaluated at various time points...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701419

    authors: Montagna D,Locatelli F,Calcaterra V,Comoli P,Moretta A,Giorgiani G,Zecca M,Bonetti F,Giraldi E,Rondini G,Maccario R

    更新日期:1998-10-01 00:00:00

  • 'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

    abstract::Several guidelines have been published about management of chronic GvHD (cGvHD), but the clinical practice still remains demanding. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) has planned a prospective observational study on cGvHD, supported by a dedicated software, including the updated recommendations. In...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2017.223

    authors: Giaccone L,Mancini G,Mordini N,Gargiulo G,De Cecco V,Angelini S,Arpinati M,Baronciani D,Bozzoli V,Bramanti S,Calore E,Cavattoni IM,Cimminiello M,Colombo AA,Facchini L,Falcioni S,Faraci M,Fedele R,Guidi S,Iori AP,M

    更新日期:2018-01-01 00:00:00

  • Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.

    abstract::Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases after allogeneic stem cell transplantation (SCT). We treated seven patients with DLI for indolent non-Hodgkin's lymphoma relapsed after SCT. In available blood and bone marrow samples, lymphoma cells were analysed by real-time quantita...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704290

    authors: Mandigers CM,Verdonck LF,Meijerink JP,Dekker AW,Schattenberg AV,Raemaekers JM

    更新日期:2003-12-01 00:00:00

  • Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation.

    abstract::Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2014.238

    authors: Shaw BE,Lee F,Krishnamurthy S,Byrne JL,Seedhouse C,Mayor NP,Maldonado-Torres H,Saudemont A,Marsh SG,Madrigal JA,Russell NH

    更新日期:2015-02-01 00:00:00

  • High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases.

    abstract::Germ cell cancer (GCC) is curable in metastatic stages. The International Germ Cell Cancer Collaborative Group (IGCCCG) reports a poor prognosis subgroup with a 5-year survival of 48%. High-dose chemotherapy with PBSC transplantation (HD-PBSCT) in these patients showed promising results in phase II, but failed to show...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/bmt.2012.14

    authors: Mohr M,Hartig I,Kessler T,Hamisch C,Kliesch S,Krug U,Spieker T,Semik M,Wiebe K,Pühse G,Hertle L,Liersch R,Müller-Tidow C,Mesters RM,Berdel WE

    更新日期:2012-10-01 00:00:00

  • Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.

    abstract::Thrombotic microangiopathy (TM), manifesting clinically as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, is an uncommon complication after bone marrow transplantation (BMT). A retrospective analysis of potential risk factors for TM following allogeneic BMT was performed. Clinical data were analyzed...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701359

    authors: Paquette RL,Tran L,Landaw EM

    更新日期:1998-08-01 00:00:00

  • Rapid and automated processing of bone marrow grafts without Ficoll density gradient for transplantation of cryopreserved autologous or ABO-incompatible allogeneic bone marrow.

    abstract::The growing number of BMTs has increased interest in safe and standardized in vitro bone marrow processing techniques. We describe our experience with a rapid automated method for the isolation of mononuclear cells (MNC) from large volumes of bone marrow using a Fenwal CS-3000 cell separator without employing density ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schanz U,Gmür J

    更新日期:1992-12-01 00:00:00

  • Alternative donor SCT for the treatment of MHC class II deficiency.

    abstract::MHC Class II deficiency is a rare primary immunodeficiency disease characterized by absent HLA Class II expression resulting in CD4 lymphopenia, lack of Ag-specific responses and recurrent infection. Without successful allogeneic SCT, most children succumb to infection within the first decade of life. To date, alterna...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.140

    authors: Small TN,Qasim W,Friedrich W,Chiesa R,Bleesing JJ,Scurlock A,Veys P,Sparber-Sauer M

    更新日期:2013-02-01 00:00:00

  • Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.

    abstract::Recombinant human (rHu) G-CSF has been widely used to treat neutropenia and mobilize PBPCs for their autologous and allogeneic transplantation. It shortens neutropenia and thus reduces the frequency of neutropenic fever. We compared the efficiency of glycosylated rHu and non-glycosylated Hu G-CSF in mobilizing hematop...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.150

    authors: Ria R,Gasparre T,Mangialardi G,Bruno A,Iodice G,Vacca A,Dammacco F

    更新日期:2010-02-01 00:00:00

  • Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.

    abstract::These recommendations were prepared by the European Conference on Infections in Leukaemia following a predefined methodology. Literature searches were made to identify studies pertinent to management of CMV, HHV-6, -7 and -8 infections. For CMV, 76 studies were reviewed: 72 published and 4 presented as abstracts. Twen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,实务指引

    doi:10.1038/bmt.2008.162

    authors: Ljungman P,de la Camara R,Cordonnier C,Einsele H,Engelhard D,Reusser P,Styczynski J,Ward K,European Conference on Infections in Leukemia.

    更新日期:2008-08-01 00:00:00

  • Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer.

    abstract::We describe the case of a HBsAg+, HBeAg+ carrier, treated with lamivudine, who experienced exacerbation of hepatitis after BMT from an anti-HBs+, anti-HBc+, anti-HBe+ donor. The serological profile of the donor and the timing of exacerbation suggested that the adoptive immunity transfer played a major pathogenetic rol...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704471

    authors: Favre C,Menconi MC,Nardi M,Casazza G,Oliveri F,Macchia P,Bonino F,Brunetto MR

    更新日期:2004-05-01 00:00:00

  • Complete heart block in association with graft-versus-host disease.

    abstract::An infant who received haploidentical BM for severe combined immunodeficiency (SCID) developed acute, reversible complete heart block in association with an exacerbation of GVHD. Respiratory distress and myocardial dysfunction were also seen with this and previous GVHD exacerbations. The patient had not received chemo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701038

    authors: Gilman AL,Kooy NW,Atkins DL,Ballas Z,Rumelhart S,Holida M,Lee N,Goldman F

    更新日期:1998-01-01 00:00:00

  • Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.

    abstract::The application of myeloablative Allo-SCT is limited by its associated morbidity and mortality. Reduced-intensity conditioning regimens attempt to diminish these, but are associated with a higher risk of disease relapse. Given the evidence of activity of clofarabine and cytarabine in myelodysplastic syndrome/acute mye...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2008.423

    authors: Martin MG,Uy GL,Procknow E,Stockerl-Goldstein K,Cashen A,Westervelt P,Abboud CN,Augustin K,Luo J,DiPersio JF,Vij R

    更新日期:2009-07-01 00:00:00

  • Pulmonary infection with microsporidia after allogeneic bone marrow transplantation.

    abstract::Microsporidia are obligate, intracellular protozoal parasites that can be pathogenic in immunocompromised individuals. The majority of cases of microsporidiosis have been documented in patients with HIV, and only a few case reports exist of infection in solid organ transplant patients. We report the first case of pulm...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704327

    authors: Teachey DT,Russo P,Orenstein JM,Didier ES,Bowers C,Bunin N

    更新日期:2004-02-01 00:00:00

  • Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.

    abstract::Graft-versus-tumour reactions as a form of adoptive immunotherapy may help prevent the recurrence of haematological malignancy following allogeneic BMT. We hypothesised that such reactions may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of cyclosporine (CYA). CYA dose ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1700961

    authors: Abraham R,Szer J,Bardy P,Grigg A

    更新日期:1997-11-01 00:00:00

  • Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD).

    abstract::A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD). Thirteen patients were treated with pilocarpine of 20 mg/day orally for 7 days, and 15 patien...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705621

    authors: Agha-Hosseini F,Mirzaii-Dizgah I,Ghavamzadeh L,Ghavamzadeh A,Tohidast-Acrad Z

    更新日期:2007-04-01 00:00:00

  • Underlying coronary artery disease and successful bone marrow transplantation: a case report.

    abstract::The cardiovascular risk of concurrent coronary artery disease in patients undergoing bone marrow transplantation (BMT) is not well known. We present a case of a 32-year-old male Hodgkin's disease patient with prior chemotherapy and radiotherapy, who underwent autologous BMT. His underlying single vessel coronary arter...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schechter D,Drakos P,Nagler A

    更新日期:1994-05-01 00:00:00

  • Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

    abstract::Reduced-intensity conditioning (RIC) extends hematopoietic stem cell transplants (HSCT) to elderly or debilitated patients who are not candidates for HSCT. The incidence and outcomes of cardiac complications have been reported following myeloablative HSCT. We assessed the incidence and outcomes of cardiac complication...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.97

    authors: Peres E,Levine JE,Khaled YA,Ibrahim RB,Braun TM,Krijanovski OI,Mineishi S,Abidi MH

    更新日期:2010-01-01 00:00:00

  • Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT.

    abstract::CY in combination with BU is a widely used conditioning regimen for haematopoietic SCT (HSCT). The aim of this study was to evaluate the pharmacokinetics (PK) of CY and its major metabolite 4-hydroxyCY (HCY) in patients with thalassemia undergoing HSCT. A total of 55 patients received BU (16 mg/kg) followed by CY (160...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.254

    authors: Balasubramanian P,Desire S,Panetta JC,Lakshmi KM,Mathews V,George B,Viswabandya A,Chandy M,Krishnamoorthy R,Srivastava A

    更新日期:2012-09-01 00:00:00

  • Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation.

    abstract::Twenty patients were treated with chemotherapy to mobilize progenitors into the blood. Peripheral blood stem cells were quantitated in peripheral blood or leukapheresis products using colony assays and flow cytometric measurement of CD34+ cells. In four patients where complete sets of serial samples were obtained, the...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bender JG,Williams SF,Myers S,Nottleman D,Lee WJ,Unverzagt KL,Walker D,To LB,Van Epps DE

    更新日期:1992-09-01 00:00:00

  • Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients.

    abstract::We conducted an observational study to assess the etiology, clinical features and outcomes of bloodstream infection (BSI) in 172 hematopoietic SCT (HCST) recipients. One hundred episodes of BSI in the pre-engraftment period (early onset) were compared with 89 episodes in the post-engraftment phase (late onset). More p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.37

    authors: Gudiol C,Garcia-Vidal C,Arnan M,Sánchez-Ortega I,Patiño B,Duarte R,Carratalà J

    更新日期:2014-06-01 00:00:00

  • Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.

    abstract::The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in pati...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.73

    authors: Mahindra A,Bolwell BJ,Rybicki L,Elder P,Kalaycio M,Dean R,Avalos B,Sobecks R,Tench S,Andresen S,Pohlman B,Sweetenham J,Devine S,Copelan E

    更新日期:2012-02-01 00:00:00

  • Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.

    abstract::Hematopoietic stem cell transplantation (HSCT) for autoimmune diseases have been, because of safety reasons, overwhelmingly autologous. Results are, in general, encouraging with improvement in quality of life, a remission of up to several years, and perhaps in some diseases improved survival. This indicates that furth...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703950

    authors: Oyama Y,Traynor AE,Barr W,Burt RK

    更新日期:2003-08-01 00:00:00

  • The bare lymphocyte syndrome.

    abstract::The bare lymphocyte syndrome is a combined immunodeficiency resulting from the lack of expression of either class I or class II HLA antigens at the cell surface. The main clinical manifestations are infections of the respiratory or the digestive tract. The immunodeficiency involves the absence of antibody formation an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Touraine JL,Marseglia GL,Betuel H,Souillet G,Gebuhrer L

    更新日期:1992-01-01 00:00:00

  • Adult respiratory syndrome following autologous bone marrow transfusion.

    abstract::Autologous bone marrow transplantation was performed in a 48-year-old man with relapsed high grade lymphoma. Two hours after the marrow infusion he developed pulmonary infiltrates and adult respiratory distress syndrome (ARDS). The aetiology of ARDS in this setting is uncertain but probably relates to pulmonary infect...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Roy V,Veys P,Jackson F,Ryan J,Lowdell M,Newland AC

    更新日期:1989-11-01 00:00:00

  • Clinical effectiveness of hyperbaric oxygen therapy for BK-virus-associated hemorrhagic cystitis after allogeneic bone marrow transplantation.

    abstract::Late-onset hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT) has been associated with BK virus (BKV). Antiviral drugs are of limited efficacy and the optimal treatment for HC has not yet been established. Hyperbaric oxygen (HBO) may benefit these patients. We, therefore, retrosp...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.228

    authors: Savva-Bordalo J,Pinho Vaz C,Sousa M,Branca R,Campilho F,Resende R,Baldaque I,Camacho O,Campos A

    更新日期:2012-08-01 00:00:00

  • Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.

    abstract::High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hematological side-effect. Amifostine is a cytoprotector which prevents toxicity induced by anticancer therapy. We p...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1703757

    authors: Thieblemont C,Dumontet C,Saad H,Roch N,Bouafia F,Arnaud P,Hequet O,Espinouse D,Salles G,Roy P,Eljaafari-Corbin A,Du Manoir-Baumgarten C,Coiffier B

    更新日期:2002-12-01 00:00:00

  • Cord blood banks collect units with different HLA alleles and haplotypes to volunteer donor banks: a comparative report from Swiss Blood stem cells.

    abstract::Allogeneic haematopoietic SCT is a standard therapy for many patients with haematological diseases. A major aim of public umbilical cord blood (UCB) banking is to establish an inventory with a large HLA diversity. Few studies have compared HLA diversity between UCB banks and volunteer unrelated donor (VUD) registries ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.391

    authors: Meyer-Monard S,Passweg J,Troeger C,Eberhard HP,Roosnek E,de Faveri GN,Chalandon Y,Rovo A,Kindler V,Irion O,Holzgreve W,Gratwohl A,Müller C,Tichelli A,Tiercy JM

    更新日期:2009-05-01 00:00:00